A Study on the Interaction Between Intestinal Microbiota, Inflammatory Cytokines, and the Expression of miR-330-3p and miR-515-5p in Patients with Ulcerative Colitis
Abstract
Background: Ulcerative colitis (UC) has a complex pathogenesis involving multiple factors. This study aims to explore the interplay among intestinal microbiota, serum inflammatory cytokines, and miR-330-3p, miR-515-5p in UC patients for novel treatment strategies.
Methods: The study enrolled 95 healthy controls, 88 UC patients in remission, and 91 in active diseases. Assessments included clinical data, intestinal microbiota detection (using culture methods), serum cytokine measurement (using ELISA assay), and miRNA expression analysis (using RT-qPCR). ROC curves evaluated diagnostic value, and multivariate logistic regression identified risk factors.
Results: From the control group to UC remission, and then to seizure UC, significant decreases were observed in Bifidobacterium, Lactobacillus counts, IL-10 levels, and miR-515-5p expression, while increases were noted in Enterobacteriaceae, Enterococcus counts, IL-6, TNF-α levels, and miR-330-3p expression (P<0.05). ROC curve analysis showed improved diagnostic accuracy for UC with the combination of miR-330-3p and miR-515-5p (AUC = 0.899, 95% CI: 0.936-0.978, sensitivity: 92.18%, specificity: 88.42%). miR-515-5p positively correlated with beneficial microbiota and IL-10 (r > 0.5, p<0.001) and negatively with harmful microbiota, IL-6, and TNF-α (r < -0.5, p < 0.001); miR-330-3p showed opposite correlations. miR-515-5p, Bifidobacterium, Lactobacillus, and IL-10 were protective factors for UC, whereas miR-330-3p, Enterobacteriaceae, Enterococcus, IL-6, and TNF-α were risk factors.
Conclusions: This study revealed interactions among intestinal microbiota, serum inflammatory cytokines, and miRNAs in UC patients, confirming the potential of miR-330-3p and miR-515-5p in UC diagnosis and assessment.
Copyright (c) 2025 Kaidi Qin, Chao Hu, Wenjun Li, Wulin Wang, zilong Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.